Patent court to review Alexion's Soliris patents on Amgen challenge: filings

The U.S. patent office will review three patents on Alexion Pharmaceuticals Inc's drug Soliris, after rival Amgen Inc filed a petition challenging them, court filings showed on Friday.

from Reuters: Health News https://ift.tt/2Pq8JyB